Cell Medica

Cell Medica

Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases.

All edits

Edits on 17 June, 2020
Charlie Hilton
Charlie Hilton approved a suggestion from Golden's AI on 17 June, 2020 5:03 pm
Edits made to:
Article (+20/-20 characters)
Article

On July 23, 2012 Cell Medica completed their series A funding round with $26.5 in funding from Wellcome Trust, Imperial InnovationsImperial Innovations, and Invesco Perpetual.

Edits on 10 June, 2020
Alex Dean
Alex Dean approved a suggestion from Golden's AI on 10 June, 2020 7:10 pm
Edits made to:
Article (+30/-30 characters)
Article

On November 25, 2014 Cell Medica completed their series B funding round with $78 million in funding from Woodford Investment ManagementWoodford Investment Management, Imperial Innovations, and Invesco Perpetual.

Edits on 1 June, 2020
Daniel Frumkin"added to article to surpass 1000 characters"
Daniel Frumkin edited on 1 June, 2020 9:31 am
Edits made to:
Article (+704 characters)
Article

Cell Medica is also known as Kuur Therapeutics. The company looks to transforming the lives of patients with cancer and is interested in the development of off-the-shelf engineered CAR-NLT cell therapies. The company's approach includes natural biology of a subset of cytotoxic T cells, and CAR construct engineering.

The company looks to develop a growing portfolio of allogeneic CAR-NKT products to treat broad populations of patients. The goal is to harness the human immune system for the treatment of cancer. They look to license and partner through opportunities to draw on global immunotherapy expertise, and maintain their mission of harnessing the human immune system for the treatment of cancer.

Edits on 28 July, 2019
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 28 July, 2019 4:45 pm
Edits made to:
Infobox (+2 properties)
Infobox
Edits on 19 March, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 March, 2019 10:46 pm
Edits made to:
Article (+14/-14 characters)
Article

On July 23, 2012 Cell Medica completed their series A funding round with $26.5 in funding from Wellcome TrustWellcome Trust, Imperial Innovations, and Invesco Perpetual.

Edits on 16 March, 2019
Dawson Sewell
Dawson Sewell edited on 16 March, 2019 1:25 pm
Edits made to:
Infobox (+9 properties)
Timeline (+3 events) (+588 characters)
Description (+95 characters)
Article (+728 characters)
People (+1 rows) (+2 cells) (+20 characters)
Further reading (+4 rows) (+16 cells) (+717 characters)
Categories (+2 topics)
Related Topics (+2 topics)
Topic thumbnail

Cell Medica

Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases.

Article

Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases that is headquartered in London, England and was founded in 2005 by Gregg Sando.

Funding

Series A

On July 23, 2012 Cell Medica completed their series A funding round with $26.5 in funding from Wellcome Trust, Imperial Innovations, and Invesco Perpetual.

Series B

On November 25, 2014 Cell Medica completed their series B funding round with $78 million in funding from Woodford Investment Management, Imperial Innovations, and Invesco Perpetual.

Series C

On March 15, 2017 Cell Medica completed their series C funding round with $74 million in funding from Touchstone Innovations, Woodford Investment Management, and Invesco Perpetual.

People

Name
Role
Related Golden topics

Gregg Sando

Founder

Further reading

Title
Author
Link
Type

CAR-T player Cell Medica names Kite's European chief as CEO

Nick Paul Taylor

Web

Privately-owned UK biotech Cell Medica has named Chris Nowers its new chief executive after its founder...

The Pharma Letter

Web

T-cell immunotherapy firm Cell Medica rakes in $78M in Imperial-led series B

Nuala Moran

Web

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Evelyn Warner

Web

Infobox
Categories
Related Topics
Timeline

March 15, 2017

Series C funding round

On March 15, 2017 Cell Medica completed their series C funding round with $74 million in funding from Touchstone Innovations, Woodford Investment Management, and Invesco Perpetual.

November 25, 2014

Series B funding round

On November 25, 2014 Cell Medica completed their series B funding round with $78 million in funding from Woodford Investment Management, Imperial Innovations, and Invesco Perpetual.

July 23, 2012

Series A funding round

On July 23, 2012 Cell Medica completed their series A funding round with $26.5 in funding from Wellcome Trust, Imperial Innovations, and Invesco Perpetual.

Dawson Sewell"Initial topic creation"
Dawson Sewell created this topic on 16 March, 2019 12:56 pm
Edits made to:
Topic thumbnail

 Cell Medica

Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.